silver has been researched along with Aerobic Glycolysis, Oncologic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Chen, CY; Du, W; He, ZH; Hong, CG; Hu, XK; Huang, J; Liu, HM; Liu, YW; Liu, ZZ; Luo, MJ; Luo, ZW; Qian, YX; Rao, SS; Situ, WY; Tan, YJ; Tang, SY; Wang, Y; Wang, YY; Wang, ZX; Wu, B; Xia, K; Xie, H; Yan, ZQ; Yin, H; Yue, T; Zhang, HQ; Zhang, Y; Zhou, JH | 1 |
1 other study(ies) available for silver and Aerobic Glycolysis, Oncologic
| Article | Year |
|---|---|
Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK.
Topics: Adolescent; Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Female; Fructose; Humans; Infant; Infant, Newborn; Injections, Intravenous; Lung Neoplasms; Male; Metal Nanoparticles; Mice; Mitochondria; Osteosarcoma; Oxidation-Reduction; Primary Cell Culture; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Reactive Oxygen Species; Renal Elimination; Signal Transduction; Silver; Tissue Distribution; Warburg Effect, Oncologic; Xenograft Model Antitumor Assays; Young Adult | 2020 |